Related Experiment Video
Updated: Sep 23, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Development of hairy cell leukemia in a patient treated with cytoreductive agents for essential thrombocythemia
Michael Azagury1, Jean-Michel Martelli, Marie Morcelet
1Department of Internal Medicine, Hematology Laboratory, Hospital of Meulan, France.
Abstract:
The association of second malignancies in hairy cell leukemia (HCL) is well recognized. Most of these malignancies are either solid tumors or lymphoproliferative disorders rather than myeloproliferative disorders. But these malignancies are usually related to a complication of the drug treatment for HCL. The chronological sequence of HCL occurring after a hematological disorder is very rarely described. This report describes the first case, to our knowledge, of a patient who developed HCL five years after essential thrombocythemia that was treated with oral cytoreductive agents. Pathogenesis of the coexistence of both diseases is discussed.